Researchers compared the risk for serious infections in offspring of mothers with chronic inflammatory diseases who received non-TNFi biologics or tofacitinib during pregnancy vs offspring who were unexposed, but exposed to TNFi in utero.
This study was conducted to describe patterns of first and subsequent TNFi use and response to long-term TNFi therapy in patients with PsA.
Researchers examined complement activation in spondyloarthropathies, before and after initiation of antirheumatic treatment, and the link between complement activation and markers of inflammation and cardiovascular risk.
Researchers examined the effect of smoking on all-cause and cause-specific discontinuation of tumor necrosis factor inhibition in patients with axial spondyloarthritis.
The model improves anti-TNF drug selection and the effect of genetic markers across multiple cohorts.
TNFi therapy failed to prevent the development of joint ankylosis despite a substantial reduction in inflammation with TNFi therapy.
Researchers assessed the risk for peripheral neuropathy with TNFi in patients with rheumatic diseases.
Effective suppression of inflammation with tumor necrosis factor inhibitor therapy decreases radiographic progression in early ankylosing spondylitis.
Patients who continued or switched their TNF inhibitor after a serious infection had a lower risk for recurrent infection compared with those who stopped the drug.
Researchers observed a higher peri- and postpartum flare rate in mothers who discontinued TNFi during the first trimester.
